The condition at the center of this research is known today as metabolic dysfunction-associated steatotic liver disease, or MASLD, a renaming that reflects the growing consensus that the disorder is fundamentally a manifestation of broader metabolic derangement rather than a liver problem in isolation. In its early stage, termed hepatic steatosis, fat droplets accumulate within hepatocytes, the primary working cells of the liver. For many individuals this process remains silent for years, but in a significant fraction it advances to inflammation and scarring, conditions that can progress to cirrhosis and liver cancer. Critically, hepatic fat accumulation is tightly linked to insulin resistance, the metabolic fault line that precedes and drives type 2 diabetes. The study by Koene and colleagues focused precisely on this vulnerable population: individuals with obesity and prediabetes who already had evidence of fatty liver, a group in which effective intervention could alter the trajectory of disease before irreversible damage occurs.

To understand why fructose has emerged as such a compelling target, one must appreciate how differently the body handles this sugar compared with glucose. While virtually every cell in the body can take up and metabolize glucose, fructose is handled primarily by the liver, the small intestine and the kidney. The first and rate-limiting step in fructose metabolism is carried out by an enzyme called ketohexokinase, also known as fructokinase, which rapidly phosphorylates fructose to fructose-1-phosphate. This reaction consumes ATP, the cellular energy currency, and unlike the tightly regulated phosphorylation of glucose, fructokinase operates with little feedback control. The result is a rapid drop in intracellular phosphate and ATP, a transient energy depletion that triggers a cascade of downstream events, including the activation of AMP deaminase and the generation of uric acid, alongside a strong signal promoting de novo lipogenesis, the synthesis of new fat from carbohydrate precursors.

In evolutionary terms, this unregulated metabolic pathway may have been an asset rather than a liability. Fructose is abundant in fruit and honey, foods that were seasonally available to our ancestors. A survival mechanism that efficiently converts fructose into fat stores and induces a mild state of insulin resistance would have helped animals fatten before periods of food scarcity, a strategy famously exploited by hibernating bears and migrating birds. The problem, as Johnson and colleagues have long argued, is that modern diets deliver fructose in refined form, particularly as sucrose and high-fructose corn syrup, in quantities and at a year-round constancy that no foraging ancestor ever encountered. The ancient fattening switch is thereby flipped continuously, promoting fat accumulation in the liver, elevated uric acid, insulin resistance and hypertension, the constellation of abnormalities that defines metabolic syndrome.

Animal studies laid the groundwork for the therapeutic hypothesis. Research published by Ishimoto and colleagues in 2012 demonstrated that mice lacking functional ketohexokinase were protected from fatty liver, weight gain and insulin resistance when consuming fructose, establishing the enzyme as the gateway through which fructose exerts its metabolic damage. Conversely, mice engineered to overexpress the enzyme in the liver or intestine showed heightened susceptibility to these outcomes. Subsequent work, including studies by Gutierrez and colleagues, refined the pharmacology of ketohexokinase inhibition and demonstrated that blocking the enzyme could reduce hepatic fat synthesis and improve metabolic parameters in preclinical models. These findings converged on a clear proposition: if fructose metabolism is a driver of fatty liver, then pharmacologically jamming that pathway might treat the disease even in the face of continued dietary exposure.

Translating that proposition into human medicine required clinical testing, and the road has been building steadily. Early-phase trials of ketohexokinase inhibitors, including studies reported by Kazierad and colleagues in 2021 and by Saxena and colleagues in 2023, evaluated the safety, tolerability and metabolic effects of such compounds in human subjects, providing proof of concept that the enzyme could be safely inhibited in people. The new study by Koene and colleagues extends this line of investigation into the population where the stakes are highest: individuals with obesity, prediabetes and metabolic dysfunction-associated steatotic liver disease. According to the commentary by Johnson, Lanaspa and Tolan, the trial demonstrated that inhibiting fructose metabolism with a ketohexokinase inhibitor improved both hepatic steatosis and insulin resistance in these participants, addressing the two central abnormalities that link fatty liver to future diabetes and cardiovascular risk.

The dual benefit is what makes the result scientifically interesting. Hepatic steatosis and insulin resistance are not merely correlated; they are mechanistically intertwined. Fat accumulation in the liver interferes with insulin signaling, impairing the hormone’s ability to suppress glucose production, while insulin resistance itself promotes further lipogenesis and fat deposition, creating a self-reinforcing loop. A therapy that interrupts fructose metabolism attacks this loop at its entry point, reducing the substrate flux that drives de novo lipogenesis while simultaneously easing the energetic and inflammatory stress that fructose metabolism imposes on hepatocytes. Whether the improvements in insulin sensitivity observed in the trial are entirely secondary to reductions in liver fat, or whether blocking fructokinase also acts through additional pathways such as reduced uric acid generation or effects on the intestinal barrier, remains a question that the commentary suggests will merit further investigation.

Enthusiasm must be tempered by the realities of drug development for a chronic, lifestyle-entangled disease. Ketohexokinase inhibitors do not eliminate fructose from the diet; they blunt the metabolic consequences of its consumption, which raises questions about long-term efficacy, the appropriate patient population, and whether partial inhibition is sufficient or whether complete blockade is required. There are also biological considerations: fructokinase is expressed in tissues beyond the liver, including the kidney and the vasculature, and its complete inhibition could have effects, beneficial or otherwise, that extend beyond hepatic fat. The competing-interest disclosures accompanying the commentary, which note that the authors hold equity in a company developing inhibitors of fructose metabolism, underscore how seriously the pharmaceutical and nutraceutical communities are taking this target, and they also serve as a reminder that independent replication and long-term safety data will be essential before such agents could enter routine clinical practice.

Nevertheless, the significance of the study lies in what it validates conceptually. For decades, the dominant explanation for fatty liver disease centered on dietary fat and overall caloric excess, and the standard prescription has been weight loss through diet and exercise, advice that is effective in principle but notoriously difficult to sustain. The fructose hypothesis reframes the problem as a specific, druggable metabolic pathway, one that can be targeted independently of, or in addition to, behavioral change. If subsequent large-scale trials confirm that ketohexokinase inhibition durably reduces liver fat, improves insulin sensitivity and prevents progression to more severe liver disease, clinicians would gain a mechanism-based therapy for a condition that currently has very few approved pharmacological options. The commentary by Johnson, Lanaspa and Tolan makes the case that the evidence has now reached the threshold where such development is justified, marking a potential turning point in the approach to one of the most common liver diseases in the world.

The broader lesson resonates beyond hepatology. The story of fructose metabolism illustrates how evolutionary physiology, basic enzymology and careful clinical trial design can converge on a therapeutic target hiding in plain sight, in this case a sugar that has been a staple of the human diet for millennia but whose refined, concentrated modern forms interact with an ancient metabolic switch in ways our biology never anticipated. As Koene and colleagues’ findings circulate through the research community, attention will turn to larger and longer trials, to the identification of biomarkers that predict which patients will benefit most, and to the possibility that combination approaches, pairing fructose pathway inhibition with existing metabolic therapies, could deliver even greater benefit. For the millions of people living with fatty livers and prediabetes, the prospect that a well-understood enzymatic bottleneck might be opened to relieve their metabolic burden is a reason for genuine, if measured, optimism.

Subject of Research: Inhibition of fructose metabolism via ketohexokinase blockade as a treatment for metabolic dysfunction-associated steatotic liver disease and insulin resistance

Article Title: Inhibiting fructose metabolism to treat fatty liver

Article References: Johnson, R. J., Lanaspa, M. A., & Tolan, D. R. (2026). Inhibiting fructose metabolism to treat fatty liver. Nature Metabolism. https://doi.org/10.1038/s42255-026-01627-4

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01627-4

Keywords: fructose metabolism, ketohexokinase, fatty liver disease, MASLD, hepatic steatosis, insulin resistance, prediabetes, obesity, de novo lipogenesis, uric acid, metabolic syndrome, clinical trial

The study, published in Nature Metabolism by Evi J. C. Koene of Maastricht University and colleagues, enrolled fifteen individuals with metabolic dysfunction-associated steatotic liver disease, or MASLD, the condition formerly known as non-alcoholic fatty liver disease. In a randomized, placebo-controlled crossover design, each participant received six weeks of treatment with PF-06835919, an oral inhibitor of ketohexokinase, and six weeks of placebo, with the order of the two periods assigned at random. The crossover architecture is a powerful one for a small trial: because every participant serves as their own control, individual differences in diet, genetics and lifestyle are largely cancelled out, allowing the drug’s metabolic effects to emerge with unusual clarity from a modest sample.

The primary question the investigators asked concerned hepatic insulin sensitivity, a parameter that is notoriously difficult to measure outside specialized research settings. The team used a two-step hyperinsulinemic euglycemic clamp combined with stable isotope tracer dilution, the gold-standard methodology for dissecting where in the body insulin is doing its work. During a clamp, insulin is infused at fixed rates while blood glucose is held constant, and the rate at which insulin suppresses the liver’s endogenous glucose production reveals how responsive the hepatic insulin signaling machinery remains. In people with fatty liver disease, this suppression is typically blunted, forcing the liver to keep releasing glucose even when the hormone is signaling it to stop, a hallmark of the prediabetic state.

After six weeks of ketohexokinase inhibition, the participants’ livers had become measurably more sensitive to insulin, even though their body weight did not change. This is a critical distinction. Many metabolic interventions, from dieting to bariatric surgery, improve insulin sensitivity largely by stripping pounds away; the new trial demonstrates that blocking fructose metabolism can deliver hepatic benefits through a mechanism that is independent of weight loss. Alongside the improvement in insulin action, proton magnetic resonance spectroscopy revealed a reduction in intrahepatic lipid content, the defining feature of MASLD, and specifically a decline in the saturated fatty acid fraction of that liver fat. Saturated fat accumulation within the liver has previously been associated with de novo lipogenesis, the process by which the liver converts excess carbohydrate into new fat, and with hepatic insulin resistance, making its reduction a particularly meaningful endpoint.

What elevates the study beyond a straightforward liver-fat story is the breadth of effects observed outside the liver. The drug improved insulin-stimulated glucose disposal, meaning skeletal muscle and other peripheral tissues took up glucose more effectively under insulin stimulation. Adipose tissue insulin sensitivity also improved, visible as better insulin-mediated suppression of plasma free fatty acid release, and the distribution of body fat shifted in a favorable direction. The researchers even detected an increase in nocturnal fat oxidation, recorded in a respiration chamber, suggesting that the participants’ overnight fuel preference tilted toward burning fat rather than carbohydrate. None of these tissues processes fructose to any meaningful degree, which raises the intriguing question of how inhibiting an enzyme concentrated in the liver can remodel metabolism throughout the body.

Part of the answer appears to lie in the blood. The treatment changed the size distribution of very low-density lipoprotein particles, the triglyceride-rich lipoproteins assembled by the liver to export fat to peripheral tissues. Particle size matters clinically: larger VLDL particles are hydrolyzed differently by lipoprotein lipase and are associated with the atherogenic dyslipidemia typical of insulin-resistant states. The team also observed changes in circulating hepatokines, proteins secreted by the liver that act as endocrine messengers to distant organs. The liver, in this view, is not merely a passive victim of fructose overload but an active conductor of whole-body metabolism, and easing its fructose-driven stress retunes the signals it sends to muscle, fat and beyond.

The molecular detail supporting this interpretation came from transcriptomic and lipidomic profiling of skeletal muscle biopsies, together with plasma lipidomics. While the authors report that the treatment affected the muscle lipid profile, the targeted analysis of genes governing fatty acid handling and non-oxidative glucose disposal suggests the peripheral improvements were not driven by wholesale rewiring of muscle gene expression. This points instead toward indirect mechanisms: a leaner, more insulin-sensitive liver exporting a less lipotoxic cargo, a healthier adipose tissue releasing fewer fatty acids into the circulation, and an altered hepatokine milieu acting on insulin target tissues. Disentangling these causal threads will require further work, but the pattern is consistent with the liver serving as the upstream driver of the systemic disturbances that define MASLD.

The trial also provided reassuring safety and mechanistic signals. Urinary fructose excretion rose markedly during treatment, exactly what one expects when the enzyme that normally metabolizes fructose is blocked and the sugar spills into the urine instead. Serum uric acid, which rises when fructose is metabolized because ATP consumption in the fructokinase reaction generates AMP that is degraded to urate, fell during ketohexokinase inhibition, a change of interest given uric acid’s own suspected role in cardiometabolic disease. Alanine aminotransferase, a marker of liver injury, was also monitored. The hereditary fructose intolerance literature, in which individuals lacking aldolase B live healthy lives provided they avoid fructose, has long suggested that blocking this pathway is survivable, and the growing clinical experience with ketohexokinase inhibitors, including earlier phase 2 trials in NAFLD that reported liver fat and inflammatory marker reductions, adds to that picture.

Context matters for interpreting the magnitude of these findings. The trial was small, with fifteen participants, and was funded by Pfizer Inc. as an investigator-initiated study, with two Pfizer employees among the co-authors. The crossover design and the use of clamp-based, spectroscopy-based and chamber-based endpoints lend credibility to the physiological claims, but a trial of this size cannot establish effects on hard clinical outcomes such as diabetes incidence or cardiovascular events. Nor does the study speak to the practical question of whether a drug is the right tool for a problem rooted in diet; randomized trials of fructose restriction, such as the FRUITLESS study, have explored the dietary route, though adherence to sugar restriction in the modern food environment remains a formidable challenge.

Even with those caveats, the study marks a conceptual advance. It demonstrates in humans that pharmacologically interrupting the first committed step of fructose metabolism improves hepatic and peripheral insulin sensitivity, reduces liver fat and its saturated fat fraction, improves adipose tissue function and nocturnal fat oxidation, and remodels the lipoprotein and hepatokine profile, all without weight loss. The implication is that a substantial share of the metabolic damage attributed to dietary fructose flows through a single, druggable enzymatic gatekeeper, and that the benefits of closing that gate extend well beyond the organs that metabolize the sugar. As ketohexokinase inhibitors progress through clinical development, the question will shift from whether the biology holds to whether it can be translated into a therapy for the hundreds of millions of people living with fatty liver disease and its downstream consequences.

Subject of Research: Effects of pharmacological ketohexokinase inhibition on insulin sensitivity and liver fat in metabolic dysfunction-associated steatotic liver disease

Article Title: Metabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trial

Article References: Koene, E. J. C., Schrauwen-Hinderling, V. B., Basset-Sagarminaga, J., Brouwers, K., Op den Kamp-Bruls, Y. M. H., Mevenkamp, J., Haans, F., Schaart, G., Kornips, E., Jorgensen, J. A., Scheijen, J. L. J. M., Schalkwijk, C. G., van Weeghel, M., Vaz, F. M., Houtkooper, R. H., Wong, E., Kersten, S., Saxena, A. R., Esler, W. P., … Brouwers, M. C. G. J. (2026). Metabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trial. Nature Metabolism. https://doi.org/10.1038/s42255-026-01626-5

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01626-5

Keywords: ketohexokinase, fructose metabolism, MASLD, fatty liver disease, insulin sensitivity, PF-06835919, hepatic fat, hyperinsulinemic clamp, hepatokines, VLDL, adipose tissue, clinical trial

The biological logic behind this strategy begins with a mutation that defines pancreatic cancer. Activating mutations in the KRAS gene occur in roughly ninety percent of pancreatic ductal adenocarcinomas, and the G12D variant, in which glycine at position twelve of the KRAS protein is replaced by aspartic acid, is the most prevalent, accounting for approximately thirty-five to forty percent of cases. KRAS-mutant cancers are famous for rewiring their metabolism, favoring glycolysis even in the presence of oxygen, the phenomenon known as the Warburg effect, while simultaneously ramping up anabolic pathways that convert nutrients into lipids, nucleotides and proteins. Yet this metabolic rewiring creates a paradox: the very enzymes that drive glycolysis also act as bottlenecks, and one of the most important of these checkpoints is the enzyme phosphofructokinase-1, or PFK1, which controls whether glucose-derived carbon flows onward through the glycolytic pathway or is diverted elsewhere.

This is where fructose enters the picture. Unlike glucose, fructose can enter glycolysis downstream of the PFK1 checkpoint. Transported into cells by the fructose-specific transporter GLUT5, encoded by the SLC2A5 gene, fructose is phosphorylated by the enzyme ketohexokinase, or KHK, to form fructose-1-phosphate. The C isoform of this enzyme, KHK-C, then channels fructose-derived carbon into dihydroxyacetone phosphate and glyceraldehyde-3-phosphate, two triose phosphates that sit squarely in the lower half of the glycolytic pathway. In effect, fructolysis allows a cancer cell to bypass one of the body’s principal metabolic control points, feeding carbon directly into the reactions that generate ATP, NADH and, critically, the precursor molecules needed for fatty acid synthesis and the pentose phosphate pathway. The review’s authors argue that KRAS G12D pancreatic cancer cells exploit this bypass with particular enthusiasm, using KHK-C-dependent fructolysis to sustain anabolic growth under the nutrient-poor, oxygen-starved conditions that characterize the pancreatic tumor microenvironment.

The evidence supporting this dependency comes from preclinical studies across multiple pancreatic cancer cell lines, including well-established models such as PANC-1, MIA-PaCa-2, Capan-2, BxPC-3, PSN-1, PaTu-8988T and the aggressive metastatic line L3.6pl. These studies indicate that fructose uptake and phosphorylation can rescue tumor cells when glucose is limiting, a situation that mirrors the glucose-depleted conditions inside real tumors, where dense stromal tissue and chaotic vasculature restrict nutrient delivery. The polyol pathway, which converts glucose to fructose inside the cell through the sequential action of aldose reductases such as AKR1B1 and sorbitol dehydrogenase, adds a second layer of complexity: tumor cells can potentially manufacture their own fructose from glucose, making fructolysis accessible even when dietary fructose is scarce. This endogenous route, the authors note, means that simply avoiding fructose in the diet is unlikely to starve these tumors, and that the enzymes of the polyol pathway, particularly AKR1B1, represent additional druggable targets in the fructose-handling machinery.

Several classes of inhibitors could, in principle, exploit this vulnerability. Blocking GLUT5 would prevent fructose from entering the cell at all. Inhibiting KHK-C would stop fructose from being phosphorylated and funneled into glycolysis. Targeting AKR1B1 would shut down the intracellular conversion of glucose into fructose, cutting off the endogenous supply. Each of these interventions has a defined biochemical rationale, and each has been explored in preclinical models of cancers that consume fructose avidly, including hepatocellular carcinoma and intestinal tumors. In KRAS G12D pancreatic cancer, the review argues, such inhibitors could deprive tumor cells of a critical anabolic lifeline precisely when they are already stressed by glucose scarcity and hypoxia, potentially pushing them past the threshold of metabolic collapse.

But the authors are careful to temper this optimism with a sobering caveat: pancreatic cancer cells are metabolically flexible, and flexibility is the enemy of single-target therapy. When one metabolic pathway is blocked, cancer cells frequently compensate by rewiring others, for example by increasing glutamine consumption through glutaminase 1, by rerouting serine synthesis through phosphoglycerate dehydrogenase, or by shifting their reliance between glycolysis, the tricarboxylic acid cycle and oxidative phosphorylation. The review catalogs this adaptive repertoire in detail, noting enzymes such as pyruvate dehydrogenase kinase 1, which suppresses mitochondrial pyruvate oxidation, the mitochondrial citrate carrier, which exports citrate for lipid synthesis, and the malic enzyme and transaminase routes that shuttle carbon between compartments. Inhibiting fructolysis alone, the authors warn, may simply induce compensatory metabolic rewiring that limits therapeutic efficacy, a pattern that has undermined many previous attempts at single-agent metabolic therapy in oncology.

This is where sodium citrate, a cheap and widely used food additive and pharmaceutical compound, enters the story in a way that few readers would anticipate. The review builds on the authors’ earlier work proposing that high-dose sodium citrate, abbreviated SCT, can act as a broad-acting metabolic inhibitor in cancer cells. Citrate is not merely a passive metabolite: it sits at the junction of glycolysis and the tricarboxylic acid cycle, and its intracellular concentration regulates key enzymes, including PFK1, which citrate inhibits, and ATP citrate lyase, which converts citrate into acetyl-CoA for fatty acid synthesis. By flooding cells with extracellular citrate, sodium citrate can perturb glycolytic flux, interfere with mitochondrial metabolism, and impose widespread metabolic stress. According to the review, experimental pancreatic cancer models harboring not only KRAS G12D but also KRAS G12C, KRAS G12V and even KRAS wild-type backgrounds respond to SCT with reduced growth, suggesting that its antitumor activity is not confined to the fructolysis-dependent G12D subset but may extend across the molecular diversity of pancreatic cancer.

The proposed combination is therefore a one-two punch: a specific fructolysis inhibitor, such as a KHK or GLUT5 blocker, delivers a targeted blow to the fructose bypass, while sodium citrate applies broader pressure on glycolytic and mitochondrial metabolism, making it harder for tumor cells to compensate through alternative routes. The authors also highlight evidence that sodium citrate may enhance the sensitivity of tumor cells to commonly used pancreatic cancer chemotherapeutics, including agents such as 5-fluorouracil, and may potentiate cytotoxic immune responses, potentially involving CD8-positive T cells and other components of the antitumor immune repertoire. If these effects hold up in rigorous testing, the combination could address two chronic weaknesses of metabolic therapy at once: incomplete pathway blockade and immune evasion.

It is essential to emphasize what this review does and does not claim. This is a synthesis of preclinical evidence and mechanistic reasoning, not the report of a completed clinical trial. No patient data demonstrate that fructolysis inhibitors or high-dose sodium citrate improve survival in pancreatic cancer, and the doses of sodium citrate discussed in experimental models far exceed ordinary dietary exposure. The authors themselves frame their conclusions as hypotheses that warrant investigation, and they explicitly suggest that the therapeutic potential of sodium citrate should be explored independently of the KRAS G12D fructolytic dependency, given its activity across multiple KRAS backgrounds. Translating these ideas into the clinic will require pharmacokinetic studies, safety assessments, carefully designed combination regimens and, ultimately, randomized trials in patients whose tumors have been molecularly characterized for KRAS mutation status and metabolic phenotype.

Nevertheless, the conceptual contribution is significant. Pancreatic ductal adenocarcinoma remains one of the few major cancers whose five-year survival has barely improved over decades, and the field urgently needs targets that exploit the specific metabolic dependencies of KRAS-mutant cells. The idea that a dietary sugar’s metabolic pathway, operating through GLUT5, KHK-C and the polyol pathway, could constitute an actionable vulnerability reframes fructose from a nutritional afterthought into a central player in tumor biochemistry. Whether the combination of fructolysis inhibition with sodium citrate can survive the gauntlet of clinical validation remains an open question, but the review provides a detailed mechanistic roadmap for testing it, and in doing so adds a provocative new chapter to the ongoing effort to outmaneuver one of medicine’s most stubborn cancers.

Subject of Research: Fructose metabolism as a therapeutic vulnerability in KRAS G12D pancreatic ductal adenocarcinoma

Article Title: Fructose metabolism in pancreatic ductal adenocarcinoma: emerging vulnerabilities in KRAS G12D tumors and therapeutic perspectives with sodium citrate

Article References: Fructose metabolism in pancreatic ductal adenocarcinoma: emerging vulnerabilities in KRAS G12D tumors and therapeutic perspectives with sodium citrate. (n.d.). https://doi.org/10.1186/s13046-026-03829-w

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03829-w

Keywords: pancreatic cancer, KRAS G12D, fructolysis, ketohexokinase, sodium citrate, cancer metabolism, Warburg effect, polyol pathway, GLUT5, targeted therapy, PDAC, metabolic vulnerability